A recent increase in psychedelic research has found that psychedelics can treat mental health disorders, including anxiety, depression, suicidal thoughts and post-traumatic stress disorder. With 90% of American adults reporting that the country is in the midst of a mental health crisis, the research seems to have come at an opportune moment.
The growing body of scientific literature has encouraged several lawmakers nationwide to consider measures to either decriminalize psychedelics or legalize them for medical use. Although the number of jurisdictions in America that allow psychedelic-assisted treatments is still low, it is expected to grow as more legislators pursue psychedelic legalization.
To achieve psychedelic reform on a national scale, a political action committee has been formed to rally political candidates who support the medical use of psychedelics such as ketamine, MDMA and psilocybin. This committee, the Psychedelic Medicine PAC, will also work to find federal funding for psychedelic research and education.
Psychedelics have attracted considerable attention from consumers as well as the medical and scientific communities as an alternative mental health treatment as current treatments aren’t always effective and are known to cause side effects. Research has shown that various psychedelics can deliver significant mental health benefits over the long-term with minimal, if any, side effects. Furthermore, hallucinogenics seem to be effective at minimal doses, and they kick in quickly, meaning patients can obtain relief from their symptoms quickly and after just one or two doses.
Lawmakers in several states have already begun working on legislation to legalize the therapeutic use of psychedelics against certain mental health disorders, and the legislative pace is expected to pick up.
Although the majority of psychedelic research is in its infancy, save for the initial studies carried out in the 1960s that first pointed to the therapeutic potential of psychedelics, existing research is conclusive enough that psychedelic-assisted therapies will become increasingly accessible over the coming years. However, much more research is needed to fully understand how psychedelics deliver their benefits before these treatments can be deployed for the mass market.
Psychedelic Medicine PAC cocfounder and executive director Ryan Rodgers says that supporting psychedelic research and education is ultimately meant to heal trauma. Given that the FDA has already approved the use of MDMA (ecstasy) in the treatment of certain mental disorders, we can expect other psychedelics to receive similar approval soon.
Melissa Lavasani, also a PAC cofounder, noted that while taking a science-driven and research approach will certainly be “very slow,” it will be the best way to make people more comfortable with the somewhat divisive topic of psychedelic-assisted therapies.
Those awareness campaigns will be the right complement to the data being uncovered and disseminated by companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) that are running psychedelic drug-development programs.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
